nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
A clinical approach to diagnosis of autoimmune encephalitis
|
Graus, Francesc |
|
2016 |
15 |
4 |
p. 391-404 14 p. |
artikel |
2 |
Adaptation of neurological practice and policy to a changing US health-care landscape
|
Gorelick, Philip B |
|
2016 |
15 |
4 |
p. 444-450 7 p. |
artikel |
3 |
AMG 334 CGRP antibody for migraine: time to celebrate?
|
Ramos, Marta L |
|
2016 |
15 |
4 |
p. 347-349 3 p. |
artikel |
4 |
Autoimmune encephalitis: paving the way for early diagnosis
|
Antoine, Jean-Christophe |
|
2016 |
15 |
4 |
p. 349-350 2 p. |
artikel |
5 |
Brain imaging in the assessment for epilepsy surgery
|
Duncan, John S |
|
2016 |
15 |
4 |
p. 420-433 14 p. |
artikel |
6 |
Corrections
|
|
|
2016 |
15 |
4 |
p. 352- 1 p. |
artikel |
7 |
Corrections
|
|
|
2016 |
15 |
4 |
p. 352- 1 p. |
artikel |
8 |
Corrections
|
|
|
2016 |
15 |
4 |
p. 352- 1 p. |
artikel |
9 |
Cruveilhier versus Charcot
|
Drouin, Emmanuel |
|
2016 |
15 |
4 |
p. 362- 1 p. |
artikel |
10 |
Encephalitis: raising awareness and collaborating in research
|
Easton, Ava |
|
2016 |
15 |
4 |
p. 353- 1 p. |
artikel |
11 |
Generic-to-generic lamotrigine switches in people with epilepsy: the randomised controlled EQUIGEN trial
|
Privitera, Michael D |
|
2016 |
15 |
4 |
p. 365-372 8 p. |
artikel |
12 |
Harnessing the integrated stress response for the treatment of multiple sclerosis
|
Way, Sharon W |
|
2016 |
15 |
4 |
p. 434-443 10 p. |
artikel |
13 |
Idiopathic rapid eye movement sleep behaviour disorder: diagnosis, management, and the need for neuroprotective interventions
|
Iranzo, Alex |
|
2016 |
15 |
4 |
p. 405-419 15 p. |
artikel |
14 |
Life after concussion: how plastic is the brain?
|
Morgan, Jules |
|
2016 |
15 |
4 |
p. 363- 1 p. |
artikel |
15 |
Michael Privitera
|
|
|
2016 |
15 |
4 |
p. 362- 1 p. |
artikel |
16 |
Myasthenia gravis: subgroup classifications
|
Li, Hai-Feng |
|
2016 |
15 |
4 |
p. 355-356 2 p. |
artikel |
17 |
Myasthenia gravis: subgroup classifications
|
Kohler, Siegfried |
|
2016 |
15 |
4 |
p. 356-357 2 p. |
artikel |
18 |
Myasthenia gravis: subgroup classifications – Authors' reply
|
Gilhus, Nils Erik |
|
2016 |
15 |
4 |
p. 357-358 2 p. |
artikel |
19 |
Neurological expertise is essential for Zika virus infection
|
Shakir, Raad |
|
2016 |
15 |
4 |
p. 353-354 2 p. |
artikel |
20 |
News in brief
|
|
|
2016 |
15 |
4 |
p. 364- 1 p. |
artikel |
21 |
Ozanimod: a better or just another S1P receptor modulator?
|
Sørensen, Per Soelberg |
|
2016 |
15 |
4 |
p. 345-347 3 p. |
artikel |
22 |
Philip B Gorelick: changing neurological practice in the USA
|
Kirby, Tony |
|
2016 |
15 |
4 |
p. 361- 1 p. |
artikel |
23 |
Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial
|
Sun, Hong |
|
2016 |
15 |
4 |
p. 382-390 9 p. |
artikel |
24 |
Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial
|
Cohen, Jeffrey A |
|
2016 |
15 |
4 |
p. 373-381 9 p. |
artikel |
25 |
South Africa: stroke units out of the blue
|
Burton, Adrian |
|
2016 |
15 |
4 |
p. 359-360 2 p. |
artikel |
26 |
The changing US health-care landscape: opportunities and challenges
|
Callaghan, Brian C |
|
2016 |
15 |
4 |
p. 351-352 2 p. |
artikel |
27 |
The safety of generic substitution in epilepsy
|
Perucca, Emilio |
|
2016 |
15 |
4 |
p. 344-345 2 p. |
artikel |
28 |
Top ten research priorities for brain and spine cavernous malformations
|
Salman, Rustam Al-Shahi |
|
2016 |
15 |
4 |
p. 354-355 2 p. |
artikel |
29 |
Zika virus: a little less speculation, a little more action
|
The Lancet Neurology, |
|
2016 |
15 |
4 |
p. 343- 1 p. |
artikel |